WO2006101839A3 - Enhanced bimatoprost ophthalmic solution - Google Patents

Enhanced bimatoprost ophthalmic solution Download PDF

Info

Publication number
WO2006101839A3
WO2006101839A3 PCT/US2006/009124 US2006009124W WO2006101839A3 WO 2006101839 A3 WO2006101839 A3 WO 2006101839A3 US 2006009124 W US2006009124 W US 2006009124W WO 2006101839 A3 WO2006101839 A3 WO 2006101839A3
Authority
WO
WIPO (PCT)
Prior art keywords
ophthalmic solution
bimatoprost ophthalmic
enhanced
enhanced bimatoprost
composition
Prior art date
Application number
PCT/US2006/009124
Other languages
French (fr)
Other versions
WO2006101839A2 (en
Inventor
Chin-Ming Chang
James N Chang
Rhett M Schiffman
R Scott Jordan
Joan-En Chang-Lin
Original Assignee
Allergan Inc
Chin-Ming Chang
James N Chang
Rhett M Schiffman
R Scott Jordan
Joan-En Chang-Lin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36613401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006101839(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ560788A priority Critical patent/NZ560788A/en
Priority to CA002585691A priority patent/CA2585691C/en
Priority to KR1020077023690A priority patent/KR101177598B1/en
Priority to ES06738208.5T priority patent/ES2324058T5/en
Priority to EP06738208.5A priority patent/EP1753434B2/en
Priority to MX2007011300A priority patent/MX2007011300A/en
Priority to DE602006006762T priority patent/DE602006006762D1/en
Priority to BRPI0607447-2A priority patent/BRPI0607447B1/en
Priority to CN2006800075548A priority patent/CN101137383B/en
Priority to AU2006227757A priority patent/AU2006227757B2/en
Priority to PL06738208T priority patent/PL1753434T5/en
Priority to AT06738208T priority patent/ATE431152T1/en
Priority to JP2006527201A priority patent/JP5367946B2/en
Priority to DK06738208.5T priority patent/DK1753434T4/en
Application filed by Allergan Inc, Chin-Ming Chang, James N Chang, Rhett M Schiffman, R Scott Jordan, Joan-En Chang-Lin filed Critical Allergan Inc
Publication of WO2006101839A2 publication Critical patent/WO2006101839A2/en
Publication of WO2006101839A3 publication Critical patent/WO2006101839A3/en
Priority to HK07108976.4A priority patent/HK1104211A1/en
Priority to NO20074390A priority patent/NO337190B1/en
Priority to IL185744A priority patent/IL185744A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Abstract

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
PCT/US2006/009124 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution WO2006101839A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CN2006800075548A CN101137383B (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution
DK06738208.5T DK1753434T4 (en) 2005-03-16 2006-03-14 Improved ophthalmic bimatoprost solution.
KR1020077023690A KR101177598B1 (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution
ES06738208.5T ES2324058T5 (en) 2005-03-16 2006-03-14 Bimatoprost ophthalmic solution improved
EP06738208.5A EP1753434B2 (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution
MX2007011300A MX2007011300A (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution.
DE602006006762T DE602006006762D1 (en) 2005-03-16 2006-03-14 IMPROVED OPHTHAMOLOGICAL BIMATOPROST SOLUTION
PL06738208T PL1753434T5 (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution
AU2006227757A AU2006227757B2 (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution
NZ560788A NZ560788A (en) 2005-03-16 2006-03-14 Ophthalmic solution comprising bimatoprost and benzalkonium chloride
BRPI0607447-2A BRPI0607447B1 (en) 2005-03-16 2006-03-14 IMPROVED BIMATOPROST OPHTHALMIC COMPOSITION
AT06738208T ATE431152T1 (en) 2005-03-16 2006-03-14 IMPROVED OPHTHAMOLOGICAL BIMATOPROST SOLUTION
JP2006527201A JP5367946B2 (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution
CA002585691A CA2585691C (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution
HK07108976.4A HK1104211A1 (en) 2005-03-16 2007-08-17 Enhanced bimatoprost ophthalmic solution
NO20074390A NO337190B1 (en) 2005-03-16 2007-08-29 Mixture for treatment of increased intraocular pressure
IL185744A IL185744A (en) 2005-03-16 2007-09-05 Enhanced bimatoprost ophthalmic solution

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/083,261 US7851504B2 (en) 2005-03-16 2005-03-16 Enhanced bimatoprost ophthalmic solution
US11/083,261 2005-03-16

Publications (2)

Publication Number Publication Date
WO2006101839A2 WO2006101839A2 (en) 2006-09-28
WO2006101839A3 true WO2006101839A3 (en) 2006-12-07

Family

ID=36613401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/009124 WO2006101839A2 (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution

Country Status (23)

Country Link
US (10) US7851504B2 (en)
EP (1) EP1753434B2 (en)
JP (3) JP5367946B2 (en)
KR (2) KR20120068051A (en)
CN (2) CN101137383B (en)
AR (1) AR055050A1 (en)
AT (1) ATE431152T1 (en)
AU (1) AU2006227757B2 (en)
BR (1) BRPI0607447B1 (en)
CA (1) CA2585691C (en)
DE (1) DE602006006762D1 (en)
DK (1) DK1753434T4 (en)
ES (1) ES2324058T5 (en)
HK (1) HK1104211A1 (en)
IL (1) IL185744A (en)
MX (1) MX2007011300A (en)
NO (1) NO337190B1 (en)
NZ (1) NZ560788A (en)
PL (1) PL1753434T5 (en)
RU (1) RU2363471C2 (en)
TW (1) TWI399207B (en)
WO (1) WO2006101839A2 (en)
ZA (1) ZA200707246B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
TWI544927B (en) 2008-03-17 2016-08-11 愛爾康研究有限公司 Pharmaceutical compositions having low concentration of surfactants for promoting bioavailability of therapeutic agents
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CN102695498A (en) * 2009-12-22 2012-09-26 阿勒根公司 Compositions & methods for lowering intraocular pressure
ES2564502T3 (en) 2010-03-17 2016-03-23 Novaliq Gmbh Pharmaceutical composition for the treatment of increased intraocular pressure
CA2806973A1 (en) * 2010-07-29 2012-02-02 Allergan, Inc. Preservative free bimatoprost solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
ES2708451T3 (en) * 2010-07-29 2019-04-09 Allergan Inc Solutions of bimatoprost and timolol without preservatives
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
JP2014515383A (en) * 2011-05-27 2014-06-30 レイショファーム ゲゼルシャフト ミット ベシュレンクテル ハフツング Ophthalmic formulation containing PGF2α analog
RU2474426C1 (en) * 2011-12-26 2013-02-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Prostamides and their analogues possessing neuroprotective action
PL3488847T3 (en) 2012-09-12 2024-04-08 Novaliq Gmbh Semifluorinated alkane compositions
CN104884006B (en) 2012-10-26 2017-12-15 弗赛特影像5股份有限公司 Ophthalmic system for sustained release drugs to eyes
US9120738B2 (en) * 2012-12-28 2015-09-01 Allergan, Inc. Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
US9308165B2 (en) * 2013-08-22 2016-04-12 Therapeutic Vision, Inc. Composition for treating ocular effects of diabetes
GR1008483B (en) 2013-12-23 2015-05-12 Rafarm Α.Ε.Β.Ε., Ophthalmic pharmaceutiacl composition and process for the preparation thereof
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9708079B2 (en) 2014-04-30 2017-07-18 The Boeing Company Mobile automated overhead assembly tool for aircraft structures
US10427254B2 (en) 2014-04-30 2019-10-01 The Boeing Company Flexible manufacturing for aircraft structures
US10017277B2 (en) 2014-04-30 2018-07-10 The Boeing Company Apparatus, system, and method for supporting a wing assembly
US9486917B2 (en) * 2014-04-30 2016-11-08 The Boeing Company Mobile automated assembly tool for aircraft structures
US10000298B2 (en) 2014-04-30 2018-06-19 The Boeing Company Metrology system for positioning assemblies
US10118714B2 (en) 2014-04-30 2018-11-06 The Boeing Company System and method for positioning an automated assembly tool relative to a structure
US9776330B2 (en) 2014-04-30 2017-10-03 The Boeing Company Crawler robot and supporting platform
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
PL3103439T3 (en) * 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Drippable ophthalmic bimatoprost gel
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
PT3355990T (en) 2015-09-30 2019-09-11 Novaliq Gmbh Semifluorinated compounds and their compositions
AU2017281296B2 (en) 2016-06-23 2021-03-11 Novaliq Gmbh Topical administration method
AU2017310520A1 (en) 2016-08-12 2019-03-21 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
CN109890374A (en) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 For treating the pharmaceutical composition of blear-eye
KR20190057338A (en) 2016-09-23 2019-05-28 노바리크 게엠베하 An ophthalmic composition comprising a cyclosporin
EP3548000B1 (en) 2017-05-11 2021-11-10 Vyluma Inc. Atropine pharmaceutical compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
USD841152S1 (en) 2017-06-27 2019-02-19 Monica S. Naylor Eye drop container
JP2020535156A (en) 2017-09-27 2020-12-03 ノバリック ゲーエムベーハー Ophthalmic composition containing latanoprost for use in the treatment of eye diseases
CA3076567A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh Ophthalmic compositions
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US20220125801A1 (en) * 2019-03-06 2022-04-28 Mankind Pharma Ltd. Ophthalmic composition of bimatoprost
WO2020252057A1 (en) * 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
WO2020263115A1 (en) 2019-06-28 2020-12-30 Общество С Ограниченной Ответственностью "Регеус" Agent for promoting hair growth
IT201900024961A1 (en) 2019-12-20 2021-06-20 Rafarm Uk Ltd Formulations of bimatoprost in 0.01% solution for the treatment of ocular hypertension
US20220409630A1 (en) 2019-10-31 2022-12-29 Rafarm SA Bimatoprost 0.01% solution compositions for the treatment of ocular hypertenstion
US11400100B2 (en) 2019-12-11 2022-08-02 Somerset Therapeutics, Llc. Effective benzalkonium chloride-free bimatoprost ophthalmic compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013119A1 (en) * 2002-08-05 2004-02-12 Allergan, Inc. The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
CA2498233A1 (en) * 2002-09-09 2004-03-18 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
US20050004074A1 (en) * 2003-07-01 2005-01-06 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304907A (en) 1972-05-10 1981-12-08 The Upjohn Company Bicyclo lactone intermediates for prostaglandin analogs
JPS4969636A (en) 1972-11-07 1974-07-05
GB1402035A (en) 1972-12-07 1975-08-06 Ici Ltd Cyclopentane derivatives
FR2239458A1 (en) 1973-07-31 1975-02-28 Aries Robert Prostaglandin amides - with antilipolytic, gonadotrophic, luteolytic, hypotensive and other activities associated with prostaglandins
US4183870A (en) 1974-01-26 1980-01-15 May & Baker Limited Cyclopentane derivatives
NL7605381A (en) 1975-05-26 1976-11-30 Schering Ag METHOD FOR PREPARING PROSTANE DERIVES AND METHOD FOR PREPARING A MEDICINAL PRODUCT WITH PROSTAGLANDIN ACTION.
US4073808A (en) 1975-12-29 1978-02-14 The Upjohn Company 2-Decarboxy-2-amino-methyl-PGA and 9-deoxy-9,10-didehydro-PGD analogs
US4128577A (en) * 1975-12-29 1978-12-05 The Upjohn Company 15-Methyl- and 16-phenoxy-PGF2 α, amides
US4032576A (en) 1976-01-08 1977-06-28
US4055602A (en) 1976-01-08 1977-10-25 The Upjohn Company 2-Decarboxy-2-hydroxy-methyl-5-oxa-17-phenyl-18,19,20-trinor-PGF-analogs
IL51877A (en) 1976-06-01 1981-09-13 Carlo Erba Sa -nor-16-benzyl or phenoxy-13,14-dehydro-prostaglandins and process for their preparation
US4123441A (en) 1976-09-22 1978-10-31 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
DE2715838A1 (en) 1977-04-05 1978-10-19 Schering Ag NEW PROSTANE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
US4100192A (en) 1977-04-18 1978-07-11 The Upjohn Company Inter-phenylene-PG amides
US4163758A (en) 1977-09-09 1979-08-07 Sagami Chemical Research Center 2-Nitroethylcyclopentane compounds and process for preparing the same
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
CA1141663A (en) 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
CH656877A5 (en) * 1981-11-27 1986-07-31 Erba Farmitalia OPTICALLY ACTIVE OR RACEMIC PROSTAGLAND DERIVATIVES.
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPS591463A (en) 1982-06-28 1984-01-06 Ono Pharmaceut Co Ltd Novel prostaglandin d analog, its preparation and antitumor agent containing the same
DE3371199D1 (en) 1982-08-24 1987-06-04 Teijin Ltd Novel 6-nitroprostaglandin derivatives, process for production thereof, and use thereof
JPS61126069A (en) * 1984-11-21 1986-06-13 Res Dev Corp Of Japan Prostaglandin derivative
JPH0611715B2 (en) 1986-03-17 1994-02-16 花王株式会社 Transdermal absorption enhancer and external preparation containing the same
US4824857A (en) 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
ATE101342T1 (en) 1988-09-06 1994-02-15 Kabi Pharmacia Ab PROSTAGLAND INDIVIDUALS FOR THE TREATMENT OF GREEN STAR OR OCULAR HYPERTENSION.
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
TW249226B (en) 1990-04-04 1995-06-11 Aderk Ueno Kk
US5270049A (en) 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
IT1256824B (en) * 1992-05-14 1995-12-21 Varian Spa PERFECTED HELIUM DETECTOR UNIT.
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
AR002194A1 (en) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT.
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
IT1313610B1 (en) 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti PROCESS FOR THE PREPARATION OF AQUEOUS FORMULATIONS FOR OPHTHALMIC USE
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
WO2002087564A1 (en) 2001-04-28 2002-11-07 The Regents Of The University Of California Class of glaucoma drugs to enhance aqueous humor outflow and lower intra-ocular pressure
US6743493B2 (en) * 2001-09-11 2004-06-01 Ward-Kraft, Inc. Composite form with imprintable magnetic card
WO2003074038A1 (en) 2002-02-28 2003-09-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
JP4836401B2 (en) 2002-04-01 2011-12-14 ロート製薬株式会社 Ophthalmic composition
US20040079671A1 (en) 2002-08-29 2004-04-29 Paramita Bandyopadhyay Medicinal product packaging
US20040115234A1 (en) 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US20050049311A1 (en) 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050276867A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DK2046382T3 (en) 2006-07-10 2016-12-12 Esbatech Alcon Biomed Res Unit scFv Antibodies which passes through the epithelial and / or endothelial layer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
WO2004013119A1 (en) * 2002-08-05 2004-02-12 Allergan, Inc. The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
CA2498233A1 (en) * 2002-09-09 2004-03-18 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US20050004074A1 (en) * 2003-07-01 2005-01-06 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOECKER ROBERT J ET AL: "Corneal and conjunctival changes caused by commonly used glaucoma medications.", CORNEA. JUL 2004, vol. 23, no. 5, July 2004 (2004-07-01), pages 490 - 496, XP009069170, ISSN: 0277-3740 *

Also Published As

Publication number Publication date
CN102240292A (en) 2011-11-16
US20110124737A1 (en) 2011-05-26
NO337190B1 (en) 2016-02-08
JP2014144983A (en) 2014-08-14
JP5899267B2 (en) 2016-04-06
CA2585691C (en) 2009-05-19
TW200700070A (en) 2007-01-01
AR055050A1 (en) 2007-08-01
KR20120068051A (en) 2012-06-26
EP1753434B1 (en) 2009-05-13
MX2007011300A (en) 2007-10-05
BRPI0607447B1 (en) 2022-09-27
HK1104211A1 (en) 2008-01-11
CN101137383A (en) 2008-03-05
EP1753434B2 (en) 2017-12-27
KR101177598B1 (en) 2012-08-27
JP5367946B2 (en) 2013-12-11
US8338479B2 (en) 2012-12-25
DE602006006762D1 (en) 2009-06-25
KR20070113292A (en) 2007-11-28
US8309605B2 (en) 2012-11-13
WO2006101839A2 (en) 2006-09-28
PL1753434T5 (en) 2018-05-30
US20140100287A1 (en) 2014-04-10
NZ560788A (en) 2010-12-24
IL185744A (en) 2015-09-24
US8772338B2 (en) 2014-07-08
DK1753434T4 (en) 2018-03-05
US8933120B2 (en) 2015-01-13
PL1753434T3 (en) 2009-09-30
RU2363471C2 (en) 2009-08-10
ES2324058T5 (en) 2018-05-22
AU2006227757B2 (en) 2011-07-14
US20130102678A1 (en) 2013-04-25
US8278353B2 (en) 2012-10-02
EP1753434A2 (en) 2007-02-21
IL185744A0 (en) 2008-01-06
US20130203854A1 (en) 2013-08-08
US20120142782A1 (en) 2012-06-07
CN101137383B (en) 2011-06-15
BRPI0607447A2 (en) 2009-09-01
ES2324058T3 (en) 2009-07-29
US8586630B2 (en) 2013-11-19
US20120142783A1 (en) 2012-06-07
CN102240292B (en) 2018-08-07
US20150087713A1 (en) 2015-03-26
US20160250225A1 (en) 2016-09-01
US8299118B2 (en) 2012-10-30
US20090149546A1 (en) 2009-06-11
AU2006227757A1 (en) 2006-09-28
ZA200707246B (en) 2008-09-25
US7851504B2 (en) 2010-12-14
DK1753434T3 (en) 2009-08-03
CA2585691A1 (en) 2006-09-28
TWI399207B (en) 2013-06-21
ATE431152T1 (en) 2009-05-15
JP2008511539A (en) 2008-04-17
JP2011148827A (en) 2011-08-04
JP5563515B2 (en) 2014-07-30
NO20074390L (en) 2007-10-15
US20060211770A1 (en) 2006-09-21
RU2007133919A (en) 2009-04-27

Similar Documents

Publication Publication Date Title
WO2006101839A3 (en) Enhanced bimatoprost ophthalmic solution
WO2006084217A3 (en) Rnai-mediated inhibition of ocular hypertension targets
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2006062731A8 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006113552A3 (en) Cyanoarylamines
MY159463A (en) Method and composition for treating ocular hypertension and glaucoma
WO2009028495A1 (en) Agent for fungal dermatitis
EP2546246A3 (en) Compounds and methods for the treatment or prevention of flavivirus infections
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
SI1608309T1 (en) 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
WO2005051328A3 (en) Amelioration of macular degeneration and other ophthalmic diseases
WO2007126364A8 (en) Use of antisecretory factors for treating intraocular hypertension
ATE359794T1 (en) 3, 7 THIAPROSTANIC ACID DERIVATIVES AS AN AGENT FOR REDUCING INTERNAL EYE PRESSURE
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007020671A3 (en) Ophthalmic compositions containing mucoadhesive polysaccharides able to promote corneal re-epithelization
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2008067382A3 (en) Rnai-mediated inhibition of aquaporin 4 for treatment of iop-related conditions
WO2006007227A3 (en) Abnormal cannabidiols for lowering intraocular pressure
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007146136A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680007554.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006738208

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006527201

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2585691

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 560788

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12007501844

Country of ref document: PH

Ref document number: 6652/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 185744

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 07092903

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/011300

Country of ref document: MX

Ref document number: 384182

Country of ref document: PL

Ref document number: 2006227757

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007133919

Country of ref document: RU

Ref document number: 1020077023690

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0607447

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1020127015064

Country of ref document: KR